A5028301750- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Bone and Joint Diseases
- Systemic Lupus Erythematosus Research
- Inflammatory Bowel Disease
- Cytokine Signaling Pathways and Interactions
- Systemic Sclerosis and Related Diseases
- Biosimilars and Bioanalytical Methods
- Erythrocyte Function and Pathophysiology
- Medical and Biological Sciences
- Health Systems, Economic Evaluations, Quality of Life
- Inflammatory Myopathies and Dermatomyositis
- Osteomyelitis and Bone Disorders Research
- Human Health and Disease
- Healthcare Systems and Public Health
- Microscopic Colitis
- Myofascial pain diagnosis and treatment
- Neurological Disorders and Treatments
- Hidradenitis Suppurativa and Treatments
- Musculoskeletal Disorders and Rehabilitation
- Blood properties and coagulation
- Tryptophan and brain disorders
VA Nasonova Scientific Research Institute of Rheumatology
2016-2025
Samara State University of Economics
2021
University of Leeds
2017
National Institute for Health Research
2017
NIHR Leeds Musculoskeletal Biomedical Research Unit
2017
Institute of Rheumatology
2016
The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic
2013
Russian Academy of Sciences
2010
To describe the radiographic phenotype of axial spondyloarthritis (SpA) according to presence HLA-B27.An international collaboration compared SpA HLA-B27 status. Patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) were collected. Radiographs read centrally, blinded clinical details. The symmetry sacroiliac joints lumbar syndesmophytes morphology (typical marginal versus atypical chunky), together modified Stoke Ankylosing Spondylitis Spine Score Psoriatic Arthritis...
By the end of first decade 21st century, spondyloarthritis studies have accumulated a certain number of terms that are obsolete, but used by physicians in their everyday speech, on one hand, and great variety different definitions, other hand. In January 2014, organizational meeting Expert Group on Spondyloarthritis, Association Rheumatologists Russia, decided its primary task should be to order terminology used this area. The authors primarily collected terms, which had been already medical...
Background: The concept of treat to target (T2T) in psoriatic arthritis (PsA) has been established recently and already shown its benefits [1]. But the long-term outcomes T2T have not studied yet. Objectives: To study 5 years (yrs) follow-up PsA patients (pts) treated according strategy at early stage. Methods: 35 (M/F–17/18) pts fulfilling CASPAR criteria, who were stage (PsA duration≤2 yrs) within 24 months (mos) analyzed. At time evaluation mean age is 42.7±11.2 yrs, median (Me) duration...
Objective We evaluated real-world treatment persistence and effectiveness at 1 year following initiation of IL-12/23 inhibitor ustekinumab or a tumour necrosis factor (TNFi) for psoriatic arthritis (PsA). Methods PsABio ( NCT02627768 ), prospective, observational study, followed patients with PsA prescribed first-line to third-line TNFi. Drug persistence, (achievement clinical Disease Activity Index Psoriatic Arthritis (cDAPSA) low disease activity (LDA)/remission minimal activity/very...
Investigate effects of gender on disease characteristics and treatment impact in patients with PsA.PsABio is a non-interventional European study PsA starting biological DMARD [bDMARD; ustekinumab or TNF inhibitor (TNFi)]. This post-hoc analysis compared persistence, activity, patient-reported outcomes safety between male female at baseline 6 12 months treatment.At baseline, duration was 6.7 6.9 years for 512 females 417 males respectively. Mean (95% CI) scores vs were: clinical Disease...
Objective : to conduct a clinical and economic analysis of the therapy for adult patients with psoriatic arthritis (PsA) using netakimab, Russian interleukin-17 inhibitor, in comparison other biological (b) targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), available on pharmaceutical market Federation. Material methods . The evaluation effectiveness was carried out from perspective healthcare system population active PsA, based results network meta-analysis. Clinical...
The aim – to develop a unified diagnostic algorithm for axial psoriatic arthritis (axPsA). Subjects and methods . 122 patients with (PsA), duration less than 10 years, were included in the study according CASPAR (The ClASsification Psoriatic ARthritis) criteria, provided they also had involvement. Axial involvement was detected case of radiographic sacroiliitis ((rSI); bilateral grade ≥2 or unilateral ≥3) SI active magnetic resonance imaging (MRI) (MRI-SI), ≥1 syndesmophyte(s) cervical...
The Russian Cross-disciplinary Consensus on the diagnositic and treatment of spondyloarthritis (SpA) in inflammatory bowel diseases (IBD) was prepared initiative Loginov Moscow Clinical Scientific Center, using Delphic system. Its purpose to consolidate opinions experts most actual issues diagnosis concomitant immuno-inflammatory (SpA IBD). An interdisciplinary approach is provided by participation leading gastroenterologists rheumatologists. working group analyzed domestic foreign...
The paper gives the recommendations for assessment of disease activity and functional status in patients with ankylosing spondylitis clinical practice, which have been developed by experts, taking into account international Russian experience managing these patients.
To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years.PsABio (NCT02627768), prospective, observational study, followed patients with PsA prescribed first-line to third-line TNFi. Persistence (achievement clinical Disease Activity PSA (cDAPSA) low disease activity (LDA)/remission minimal activity/very LDA (MDA/VLDA)) were assessed every 6 months. Safety data collected years....
Objective – to compare clinical characteristics of patients with axial spondyloarthritis (axSpA)/ankylosing spondylitis (AS) and psoriatic arthritis (axPsA). Subjects methods . 100 were examined: 45 axSpA/AS (group 1), 55 axPsA 2). Patients group 1 included according criteria, 2 CASPAR (ClASsification criteria for Psoriatic ARthritis) having involvement Axial was detected in case radiologically significant sacroiliitis (bilateral grade ≥2 or unilateral ≥3) active MRI sacroiliitis, ≥1...
Aim to identify outdated terms and make changes the terminology of spondyloarthritis.At first stage work, divided into two categories: "outdated" definitions that need be improved or unified. Subsequently, each member Expert Group Spondyloarthritis at Association Rheumatologists Russia (ExSpA) presented by its own definition designated term agreed with previous term. At next stage, existing were put together. After discussion, experts left a scored least 2/3 votes. The special opinion was...
Spondyloarthritis (SpA) comprises a number of inflammatory rheumatic diseases with overlapping clinical manifestations. Strong association several HLA-I alleles and T cell infiltration into an inflamed joint suggest involvement cells in SpA pathogenesis. In this study, we performed high-throughput repertoire profiling synovial fluid (SF) peripheral blood (PB) samples collected from large cohort patients. We showed that is enriched expanded clones are shared between patients similar HLA...
In recent years, there has been a considerable rise in the incidence of psoriatic arthritis (PsA) and an increase number cases its severe course, which leads to marked deterioration quality life (QL), disability early disability. PsA is characterized by chronic progressive development joint destruction ankylosis, multiple intra-articular osteolysis, spondylitis frequently accompanied various comorbidities. The important aspects prevention functional disorders erosion their successful therapy...
Objectives To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors low disease activity (LDA)/remission. Methods PsABio is a prospective, observational cohort study patients with psoriatic arthritis (PsA) at 92 sites in eight European countries, who received first-line to third-line or TNFi. Comparative achievement 6 months clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) LDA/remission, and minimal (MDA)/very LDA...
Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present results 24-weeks double blind period PATERA study. Objective . The objective study was evaluate efficacy and safety NTK compared placebo in patients with arthritis (PsA). Patients methods 194 active PsA an inadequate response previous therapy nonsteroidal anti-inflammatory drugs, conventional...
To study and compare the clinical imaging characteristics of psoriatic arthritis (PsA) in men women.
The paper gives recommendations for the drug therapy of axial spondyloarthritides, which have been developed by the Spondyloarthritis Study Group Experts. describe patient management tactic in most common clinical situations, is aimed at maximizing efficacy and safety treatment.
Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease that, on the one hand, considered as most common comorbidity in psoriasis part of systemic psoriatic disease, and, other, classified clinical form spondyloarthritis and lies at interface basic problems rheumatology dermatology. The study evolution relation to development PsA research priority area dermatology, which important for deciphering nature heterogeneity immunopathogenesis mechanisms these diseases developing novel...
Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in development wide spectrum human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic inflammatory bowel diseases, etc. This served as an incentive design new biological agents and small molecules, main mechanism action is based on blocking effects interleukin-17 (IL-17), others are associated with cells cytokines or...
Despite great advances in the diagnosis and treatment of Immune-mediated inflammatory diseases (IMIDs), which have led to a significant improvement prognosis many patients, central medical problems this pathology – restoring quality life reducing mortality population level are far from being resolved. This served as powerful stimulus for study new approaches pharmacotherapy IMIDs, one is associated with discovery targets small-molecule therapeutics that inhibit intracellular “signaling”...